公开(公告)号：US09925146B2

公开(公告)日：2018-03-27

申请号：US14841829

申请日：2015-09-01

申请人： GRÜNENTHAL GMBH

发明人： Lutz Barnscheid ,  Eric Galia ,  Sebastian Schwier ,  Ulrike Bertram ,  Anja Geissler ,  Kornelia Griessmann ,  Johannes Bartholomäus

IPC分类号： A61K31/44 ,  A61K9/20 ,  A61K9/28 ,  A61K31/485

CPC分类号： A61K9/2013 ,  A61K9/20 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/284 ,  A61K31/485

摘要： A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

公开(公告)号：US10335373B2

公开(公告)日：2019-07-02

申请号：US13864450

申请日：2013-04-17

申请人： GRÜNENTHAL GMBH

发明人： Klaus Wening ,  Lutz Barnscheid ,  Sebastian Schwier

IPC分类号： A61K9/20 ,  A61K31/135 ,  A61K9/00

摘要： A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

公开(公告)号：US09655853B2

公开(公告)日：2017-05-23

申请号：US15166573

申请日：2016-05-27

申请人： GRÜNENTHAL GMBH

发明人： Lutz Barnscheid ,  Jessica Redmer ,  Sebastian Schwier

IPC分类号： A61K47/32 ,  A61K31/74 ,  A61K9/20 ,  A61K31/135

CPC分类号： A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/135 ,  A61K47/32

摘要： The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising a pharmacologically active compound, an anionic polymer bearing carboxylic groups, wherein the content of the anionic polymer is ≧20 wt.-%, based on the total weight of the pharmaceutical dosage form, and a nonionic surfactant.

公开(公告)号：US20170296472A1

公开(公告)日：2017-10-19

申请号：US15636957

申请日：2017-06-29

申请人： GRÜNENTHAL GMBH

发明人： Lutz BARNSCHEID ,  Anja Geissler ,  Klaus Wening ,  Stefanie Strauch ,  Jana Pätz ,  Sebastian Schwier

IPC分类号： A61K9/20 ,  A61K31/485 ,  A61K31/167 ,  A61K9/24 ,  A61K45/06

CPC分类号： A61K9/2086 ,  A61K9/2031 ,  A61K9/209 ,  A61K9/2095 ,  A61K31/167 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical dosage form comprising (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further segment (S2), which contains a second pharmacologically active ingredient (A2) and provides immediate release thereof, wherein the at least one formed segment (S1) exhibits a higher breaking strength than the at least one further segment (S2) and the at least one formed segment (S1) exhibits a breaking strength of more than 500 N.

公开(公告)号：US10064945B2

公开(公告)日：2018-09-04

申请号：US13891306

申请日：2013-05-10

申请人： GRÜNENTHAL GMBH

发明人： Lutz Barnscheid ,  Eric Galia ,  Anja Geißler ,  Jana Pätz ,  Sebastian Schwier ,  Julia Baronsky-Probst

IPC分类号： A61K47/10 ,  A61K31/137 ,  A61K9/20

摘要： A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.

公开(公告)号：US09737490B2

公开(公告)日：2017-08-22

申请号：US14287348

申请日：2014-05-27

申请人： GRÜNENTHAL GMBH

发明人： Lutz Barnscheid ,  Anja Geiβler ,  Klaus Wening ,  Stefanie Strauch ,  Jana Pätz ,  Sebastian Schwier

IPC分类号： A61K9/22 ,  A61K9/20 ,  A61K31/485 ,  A61K31/167 ,  A61K45/06 ,  A61K9/24

CPC分类号： A61K9/2086 ,  A61K9/2031 ,  A61K9/209 ,  A61K9/2095 ,  A61K31/167 ,  A61K31/485 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical dosage form comprising (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further segment (S2), which contains a second pharmacologically active ingredient (A2) and provides immediate release thereof, wherein the at least one formed segment (S1) exhibits a higher breaking strength than the at least one further segment (S2) and the at least one formed segment (S1) exhibits a breaking strength of more than 500 N.

公开(公告)号：US20170071862A1

公开(公告)日：2017-03-16

申请号：US15260643

申请日：2016-09-09

申请人： GRÜNENTHAL GMBH

发明人： KLAUS WENING ,  Sebastian Schwier ,  Ulrike Bertram

IPC分类号： A61K9/20 ,  A61K31/167 ,  A61K31/137 ,  A61K31/485

CPC分类号： A61K9/2022 ,  A61K9/1641 ,  A61K9/1694 ,  A61K9/2054 ,  A61K9/4808 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/485

摘要： The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.

摘要翻译： 本发明涉及药物剂型，其特别可用于在意外或故意同时施用含有总体超治疗剂量的药理学活性成分的多种剂型之后防止其中所含的药理学活性成分过量。

公开(公告)号：US20160199306A1

公开(公告)日：2016-07-14

申请号：US15073920

申请日：2016-03-18

申请人： Grünenthal GmbH

发明人： Sebastian Schwier ,  Marcel Haupts ,  Udo Rüttgers ,  Lutz Barnscheid ,  Jana Pätz

IPC分类号： A61K9/20 ,  A61K31/137 ,  A61K9/28 ,  A61K31/135

CPC分类号： A61K9/2077 ,  A61K9/2031 ,  A61K9/2081 ,  A61K9/28 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/485

摘要： The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.

公开(公告)号：US10695297B2

公开(公告)日：2020-06-30

申请号：US16416532

申请日：2019-05-20

申请人： Grünenthal GmbH

发明人： Sebastian Schwier ,  Marcel Haupts ,  Udo Rüttgers ,  Lutz Barnscheid ,  Jana Denker

IPC分类号： A61K9/20 ,  A61K31/135 ,  A61K9/28 ,  A61K31/137 ,  A61K31/138 ,  A61K31/485

摘要： The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.

公开(公告)号：US20190110992A1

公开(公告)日：2019-04-18

申请号：US16158745

申请日：2018-10-12

申请人： Grünenthal GmbH

发明人： Carmen Stomberg ,  Harald Paul ,  Klaus Wening ,  Sebastian Schwier

IPC分类号： A61K9/14 ,  A61K31/485 ,  A61K31/137

摘要： The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.